# ERYTHROMYCIN ETHYLSUCCINATE
> **ANDA216212** · Abbreviated New Drug Application (Generic) · Sponsor: CADILA PHARMS LTD · Approved 2022-11-21
## Drug
- **FDA Application Number:** ANDA216212
- **Application type:** Abbreviated New Drug Application (Generic)
- **Brand name:** ERYTHROMYCIN ETHYLSUCCINATE
- **Generic name:** ERYTHROMYCIN ETHYLSUCCINATE
- **Active ingredients:** ERYTHROMYCIN ETHYLSUCCINATE
- **Dosage form:** GRANULE
- **Route:** ORAL
- **Marketing status:** Prescription
- **Sponsor:** CADILA PHARMS LTD
- **Manufacturer:** Cadila Pharmaceuticals Limited
- **First approval:** 2022-11-21
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216212)
---
*AI Analytics · CC0 1.0*